Evidence map›Paper›PMID 35537113›Full record

ArticleBlood advances2022

Code status transitions in patients with high-risk acute myeloid leukemia.

Hannah R Abrams, Ryan D Nipp, Lara Traeger, Mitchell W Lavoie, Matthew J Reynolds, Nneka N Ufere, Annie C Wang, Kofi Boateng, Thomas W LeBlanc, Areej El-Jawahri

Abstract read
In one paragraph

Article in Blood advances, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Hannah R AbramsDepartment of Medicine, and.ORCID 0000-0003-1044-7757
Ryan D NippMassachusetts General Cancer Center, Massachusetts General Hospital, Boston MA.ORCID 0000-0002-4577-3248
Lara TraegerMassachusetts General Cancer Center, Massachusetts General Hospital, Boston MA.
Mitchell W LavoieMassachusetts General Cancer Center, Massachusetts General Hospital, Boston MA.
Matthew J ReynoldsMassachusetts General Cancer Center, Massachusetts General Hospital, Boston MA.
Nneka N UfereDepartment of Medicine, and.ORCID 0000-0001-8255-9374
Annie C WangMassachusetts General Cancer Center, Massachusetts General Hospital, Boston MA.ORCID 0000-0003-4884-2007
Kofi BoatengMassachusetts General Cancer Center, Massachusetts General Hospital, Boston MA.
Thomas W LeBlancDepartment of Medicine, Harvard Medical School, Boston, MA; and.ORCID 0000-0002-0546-7895
Areej El-JawahriMassachusetts General Cancer Center, Massachusetts General Hospital, Boston MA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Patients with high-risk acute myeloid leukemia (AML) often experience intensive medical care at the end of life (EOL), including high rates of hospitalizations and intensive care unit (ICU) admissions. Despite this, studies examining code status transitions are lacking. We conducted a mixed-methods study of 200 patients with high-risk AML enrolled in supportive care studies at Massachusetts General Hospital between 2014 and 2021. We defined high-risk AML as relapsed/refractory or diagnosis at age ≥60. We used a consensus-driven medical record review to characterize code status transitions. At diagnosis, 86.0% (172/200) of patients were "full code" (38.5% presumed, 47.5% confirmed) and 8.5% had restrictions on life-sustaining therapies. Overall, 57.0% of patients experienced a transition during the study period. The median time from the last transition to death was 2 days (range, 0-350). Most final transitions (71.1%) were to comfort measures near EOL; only 60.5% of patients participated in these last transitions. We identified 3 conversation types leading to transitions: informative conversations focusing on futility after clinical deterioration (51.0%), anticipatory conversations at the time of acute deterioration (32.2%), and preemptive conversations (15.6%) before deterioration. Younger age (B = 0.04; P = .002) and informative conversations (B = -2.79; P < .001) were associated with shorter time from last transition to death. Over two-thirds of patients were "presumed full code" at diagnosis of high-risk AML, and most experienced code status transitions focused on the futility of continuing life-sustaining therapies near EOL. These results suggest that goals-of-care discussions occur late in the illness course for patients with AML and warrant interventions to increase earlier discussions regarding EOL preferences.

Indexed as

Leukemia, Myeloid, AcuteTerminal CareHospitalizationHumans

Identifiers

PMID35537113
PMCPMC9327548

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.